Sugi Predict

Sugi Predict / Targets / SIGLEC7

SIGLEC7

Sialic acid-binding Ig-like lectin 7 · Q9Y286 · SIGLEC7 on Sugi Atlas →

5,387 patent compounds predicted against SIGLEC7, 3,584 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL621891 SCHEMBL621891 0.51 7/20
SCHEMBL9483084 SCHEMBL9483084 0.51 7/20
SCHEMBL15397227 SCHEMBL15397227 0.51 7/20
SCHEMBL15397228 SCHEMBL15397228 0.51 7/20
SCHEMBL15090247 SCHEMBL15090247 0.50 7/20
SCHEMBL442944 SCHEMBL442944 0.49 7/20
SCHEMBL1487630 SCHEMBL1487630 0.48 7/20
SCHEMBL8472605 SCHEMBL8472605 0.48 7/20
SCHEMBL13953351 SCHEMBL13953351 0.48 7/20
SCHEMBL2742889 SCHEMBL2742889 0.47 7/20
SCHEMBL7066109 SCHEMBL7066109 0.47 7/20
SCHEMBL8489507 SCHEMBL8489507 0.47 7/20
SCHEMBL13125452 SCHEMBL13125452 0.47 7/20
SCHEMBL569911 SCHEMBL569911 0.47 7/20
SCHEMBL4926768 SCHEMBL4926768 0.47 7/20
SCHEMBL3746151 SCHEMBL3746151 0.47 7/20
SCHEMBL7531957 SCHEMBL7531957 0.47 7/20
SCHEMBL8664558 SCHEMBL8664558 0.47 7/20
SCHEMBL14985139 SCHEMBL14985139 0.46 7/20
SCHEMBL7472341 SCHEMBL7472341 0.46 7/20

Clinical trials — most relevant to SIGLEC7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) PHASE1/PHASE2UNKNOWN
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) PHASE2COMPLETED
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) PHASE1/PHASE2RECRUITING
GD2/CD56 Bi-specific CAR-T Cell Therapy PHASE1/PHASE2RECRUITING
Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma PHASE2COMPLETED
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells PHASE1/PHASE2RECRUITING
Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft PHASE2WITHDRAWN
Daratumumab in Combination With ATRA PHASE1/PHASE2COMPLETED
GD2/CD70 Bi-specific CAR-T Cell Therapy PHASE1/PHASE2RECRUITING
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia PHASE1COMPLETED
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma PHASE1COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases PHASE1COMPLETED
Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection PHASE1UNKNOWN
The Phase I Study of SIG001 Antibody on Cancer Therapy. PHASE1NOT_YET_RECRUITING
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine PHASE1COMPLETED
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies PHASE1UNKNOWN
Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies EARLY_PHASE1UNKNOWN
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies EARLY_PHASE1UNKNOWN
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes nanCOMPLETED
Galectin-3 Binding Protein in Cardiovascular Disease and Chronic Heart Failure nanCOMPLETED
Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease nanCOMPLETED
Study of Blood Immune Cells in Cancer Patients Compared to Controls nanUNKNOWN
LoViReT (Low Viral Reservoir Treated Patients) nanCOMPLETED
Effect of Enteral Bovine Lactoferrin in Preterm Infants nanCOMPLETED
Is in Vitro Maturation of Oocytes Influenced by the Origin of Gonadotropins Used in Maturation Medium: is There a Difference in Efficiency When Using Urinary Versus Recombinant Produced Follicle Stimulating Hormone and Human Chorionic Gonadotropin nanUNKNOWN
Study of the Link Between Complement Activation and IgA Nephropathy Severity nanRECRUITING
Proteomics & Glyco-Proteomic Analysis of Follicular Fluid nanUNKNOWN
Glycan Attachment Specificity, Toward ROtavirus Vaccine IMprovement GASTROVIMc (Clinical Investigation) nanCOMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Burning Mouth Syndrome: Effects of Occlusal Splint Therapy nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SIGLEC7 binder may also engage these)

ProteinNameSimilarity
Q95LH0 — 1.000 Q95LH0 →
SIGLEC9 Sialic acid-binding Ig-like lectin 9 1.000 landscape →
Q9NYZ4 — 1.000 Q9NYZ4 →
O43699 — 1.000 O43699 →
Q96PQ1 — 0.999 Q96PQ1 →
Q91Y57 — 0.998 Q91Y57 →
P20138 — 0.994 P20138 →
O15389 — 0.994 O15389 →
Q08ET2 — 0.994 Q08ET2 →
Q920G3 — 0.994 Q920G3 →
Q80ZE3 — 0.992 Q80ZE3 →
Q96LC7 — 0.991 Q96LC7 →
Q6DN72 — 0.990 Q6DN72 →
A6NMB1 — 0.990 A6NMB1 →
Q96RL6 — 0.988 Q96RL6 →
Q64JA4 — 0.987 Q64JA4 →
Q13291 — 0.987 Q13291 →
B6A8C7 — 0.984 B6A8C7 →
Q8R4Y0 — 0.983 Q8R4Y0 →
Q7TSN2 — 0.982 Q7TSN2 →
Q68SN8 — 0.982 Q68SN8 →
P43630 — 0.982 P43630 →
Q96A28 — 0.981 Q96A28 →
B6A8R8 — 0.981 B6A8R8 →
Q9HBG7 — 0.980 Q9HBG7 →
P43628 — 0.979 P43628 →
Q28125 — 0.978 Q28125 →
Q8TDQ1 — 0.978 Q8TDQ1 →
P43629 — 0.978 P43629 →
Q60513 — 0.978 Q60513 →